| Literature DB >> 34917678 |
Muhammad A Bashar1,2, Jacqui Miot3, Evan Shoul3, Robyn L van Zyl1.
Abstract
BACKGROUND: Antibiotics are miracles of science and critical for many surgical procedures. However, the emergence of multidrug resistant pathogens resulting from inappropriate antibiotic use is a threat to modern medicine. This study aimed to determine the appropriateness of antibiotic use, cost, consumption and impact of an antibiotic stewardship intervention round in a surgical ward setting.Entities:
Keywords: South Africa; antibiotic; antibiotic prophylaxis; antibiotic resistance; antibiotic stewardship; antibiotic usage; surgery; surgical site infection
Year: 2021 PMID: 34917678 PMCID: PMC8661296 DOI: 10.4102/sajid.v36i1.307
Source DB: PubMed Journal: S Afr J Infect Dis ISSN: 2312-0053
Gyssen’s algorithms for evaluation of the appropriateness of antimicrobial drug therapy.
| Category | Reason categorisation |
|---|---|
| I | Agree with the use of antimicrobial therapy/ prophylaxis, the prescription is definitely appropriate |
| II | The antimicrobial drug therapy/prophylaxis prescription is inappropriate due to: |
| IIa | 1. improper dosage |
| IIb | 2. improper dosage interval |
| IIc | 3. improper route |
| III | The antimicrobial drug therapy/prophylaxis prescription is inappropriate due to: |
| IIIa | 1. excessive length |
| IIIb | 2. duration too short |
| IV | The antimicrobial drug therapy/prophylaxis prescription is inappropriate due to: |
| IVa | 1. more effective alternative agent (Aa): specify |
| IVb | 2. less toxic Aa: specify |
| IVc | 3. less expensive Aa: specify |
| IVd | 4. less broad spectrum Aa: specify |
| V | The antimicrobial drug therapy/prophylaxis prescription is unjustified: use of any antimicrobial is not indicated |
| VI | Records insufficient for categorisation. |
Gyssens IC, Van Den Broek PJ, Kullberg B-J, Hekster YA, Van Der Meer JW. Optimizing antimicrobial therapy. A method for antimicrobial drug use and evaluation. J Antimicrob Chemother. 1992;30(5):724–727. https://doi.org/10.1093/jac/30.5.724
Patient demographics and clinical indicators.
| Variables | Baseline stage (%) | ASP stage (%) |
|
|---|---|---|---|
| Demographics | - | - | - |
| Number of patients | 264 | 212 | - |
|
| 0.501 | ||
| Male | 150 (56.82) | 114 (53.77) | - |
| Female | 114 (43.18) | 98 (46.23) | - |
| Age (years) Mean + s.d. | 45.77 ± 16.81 | 51.50 ± 15.91 | 0.01 |
| LOS (days) | 8.33 ± 7.58 | 13.44 ± 11.83 | 0.01 |
| DoT for therapeutic purposes (days) | 4.74 ± 4.58 | 3.96 ± 2.04 | 0.01 |
| Antibiotic consumption (DDD/1000 patient days) | 739.30 | 564.93 | 0.038 |
| Total number of antibiotic prescriptions (percentage of inappropriate antibiotic used therapeutically) | 443 (35) | 442 (26) | 0.006 |
| Total prescriptions administered IV | 396 (89.39) | 372 (84.16) | 0.341 |
| Appropriately prescribed IV antibiotics | 252 (56.90) | 269 (60.80) | 0.302 |
ASP, antibiotic stewardship programmes; s.d., standard deviation, LOS, length of hospital stay; DoT, duration of antibiotic therapy;DDDs, defined daily doses; IV, intravenous.
p values calculated using the chi-square test or t-test where appropriate.
Appropriateness of peri-operative antibiotic prophylaxis.
| Variables | Baseline stage (%) | ASP stage (%) |
|---|---|---|
| Overall inappropriate use | 64 | 59 |
| Inappropriateness due to agent choice | 65 | 62 |
| Inappropriateness due to duration more than 24 h | 7.3 | 6.6 |
| Time of the administration of the first dose | Not assessed | Not assessed |
ASP, antibiotic stewardship programmes.
FIGURE 1Trend of antibiotic consumption over the study period.
Frequency of top 10 antibiotic prescribed over a 10-month period in the general and vascular surgical wards.
| Name of antibiotics | Number of prescriptions (%) at baseline stage | Number of prescriptions (%) at ASP stage | Difference in number (%) of prescriptions issued | |||
|---|---|---|---|---|---|---|
|
| % |
| % |
| % | |
| Amoxicillin/clavulanic acid | 233 | 52.59 | 149 | 33.71 | ↑ 84 | 18.88 |
| Piperacillin/tazobactam | 72 | 16.26 | 115 | 26.02 | ↓ –43 | −9.76 |
| Cefazolin | 36 | 8.13 | 31 | 7.21 | ↑ 5 | 0.92 |
| Metronidazole | 20 | 4.52 | 18 | 4.07 | ↑ 2 | 0.45 |
| Fluconazole | 13 | 2.93 | 19 | 4.29 | ↓ –6 | −1.36 |
| Vancomycin | 10 | 2.26 | 6 | 1.39 | ↑ 4 | 0.87 |
| Cloxacillin | 7 | 1.58 | 3 | 0.68 | ↑ 4 | 0.90 |
| Imipenem | 7 | 1.58 | 8 | 1.81 | ↓ –1 | −0.23 |
| Ciprofloxacin | 6 | 1.35 | 13 | 2.72 | ↓ –7 | −1.37 |
| Ertapenem | 2 | 0.45 | 18 | 4.07 | ↓ –16 | −3.62 |
| Others | 37 | 8.35 | 62 | 14.03 | ↓ –25 | −5.68 |
| Total | 443 | 100.00 | 442 | 100.00 | - | - |
ASP, antibiotic stewardship programmes.
Antibiotic therapy based on clinical indications.
| Clinical indications | Baseline stage number of prescription (%) | ASP stage number of prescription (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vascular ward | General ward | Total of both wards | Vascular ward | General ward | Total of both wards | |||||||
|
| % |
| % |
| % |
| % |
| % |
| % | |
| Empiric | 58 | 56.31 | 186 | 54.71 | 244 | 55.08 | 82 | 56.94 | 158 | 53.02 | 240 | 54.30 |
| Prophylaxis | 32 | 31.07 | 95 | 27.94 | 127 | 28.67 | 37 | 25.69 | 60 | 20.13 | 97 | 21.95 |
| Targeted | 12 | 11.65 | 55 | 16.18 | 67 | 15.12 | 25 | 17.37 | 63 | 21.15 | 88 | 19.90 |
| Prokinetic | 1 | 0.97 | 4 | 1.17 | 5 | 1.13 | 0 | 0.00 | 17 | 5.70 | 17 | 3.85 |
|
| ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASP, antibiotic stewardship programmes.
Pathogens isolated in the two stages of the study.
| Cultured pathogens | Baseline stage | ASP stage |
|
|---|---|---|---|
|
| 21 | 22 | 0.46 |
|
| 18 | 29 | 0.01 |
|
| 17 | 23 | 0.27 |
| Methicillin-sensitive | 12 | 5 | 0.001 |
|
| 1 | 11 | 0.001 |
|
| 11 | 5 | 0.01 |
|
| 7 | 15 | 0.01 |
|
| 5 | 8 | 0.032 |
| Coagulase-negative | 5 | 13 | 0.01 |
| Methicillin-resistant | 4 | 8 | 0.02 |
|
| 4 | 2 | - |
|
| 15 | 15 | - |
|
| 9 | 9 | - |
|
| - | 3 | - |
|
| - | 3 | - |
|
| 4 | 1 | - |
|
| 3 | - | - |
|
| - | 2 | - |
|
| - | 2 | - |
|
| - | 2 | - |
|
| - | 2 | - |
|
| - | 2 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| - | 1 | - |
|
| 3 | 8 | - |
|
| 3 | 2 | - |
|
| 2 | 1 | - |
|
| 2 | - | - |
|
| 2 | - | - |
|
| 2 | - | - |
|
| 2 | - | - |
|
| 1 | 1 | - |
|
| 1 | - | - |
|
| 1 | 1 | - |
|
| 1 | - | - |
|
| 1 | - | |
|
| 1 | - | - |
|
| 1 | 1 | - |
|
| 1 | - | - |
|
| 1 | - | - |
|
| |||
|
|
|
|
|
ASP, antibiotic stewardship programmes.
Consumption of most frequently used agents.
| Most used antibiotics | Indication | ||
|---|---|---|---|
| Prophylaxis (95% CI) | Empiric (95% CI) | Targeted (95% CI) | |
|
| |||
| Amoxicillin/clavulanic acid | 28.14 (21.66–34.63) | 170.69 (147.14–194.24) | 28.26 (19.21–37.31) |
| Piperacillin/tazobactam | - | 147.57 (61.86–233.29) | 22.91 (15.07–30.74) |
| Fluconazole | 52.08 | 83.14 (49.14–117.15) | - |
| Metronidazole | 0.15 | 19.46 (7.35–31.57) | 3.87 (1.73–6.00) |
| Cefazolin | 7.99 (6.75–9.24) | - | - |
|
| |||
| Amoxicillin/clavulanic acid | 12.41 (8.45–16.38) | 107.05 (89.76–124.33) | 14.05 (7.12–20.98) |
| Piperacillin/tazobactam | - | 90.16 (79.30–100.93) | 27.68 (21.54–33.83) |
| Fluconazole | 12.13 (9.32–14.93) | 79.53 (47.52–111.54) | 23.54 (2.49–44.58) |
| Ertapenem | - | 5.35 (3.58–7.11) | 21.04 (13.97–28.11) |
| Cefazolin | 11.06 (6.25–15.87) | - | - |
ASP, antibiotic stewardship programmes; CI, confidence interval, DDD, defined daily doses.